99mTc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
2002

Concerns About Radiolabelled Liposomal Doxorubicin in Brain Tumours

Commentary Evidence: moderate

Author Information

Author(s): Laverman P, Boerman O C, Storm G, Oyen W J G

Primary Institution: University Medical Center Nijmegen

Conclusion

The authors express concerns about the labelling method and imaging protocol used in previous studies on radiolabelled liposomal doxorubicin.

Supporting Evidence

  • The labelling method used may yield an unstable product.
  • Only 1% of the radiolabelled activity was associated with the liposomes in their analysis.
  • Imaging was performed too early, potentially misrepresenting the results.

Takeaway

The way the liposomes were labelled might not work well, and the imaging done too early could lead to misleading results.

Methodology

The authors attempted to reproduce a labelling method and analyzed the labelling mixture using chromatography techniques.

Potential Biases

Potential bias in interpreting the results of the original studies due to the authors' vested interest in alternative methods.

Limitations

The commentary does not provide original experimental data but critiques previous studies.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600093

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication